ENGOT-en9/LEAP-001: A phase III, randomized, active-controlled, open-label study of pembrolizumab plus lenvatinib versus paclitaxel plus carboplatin for newly diagnosed advanced or recurrent endometrial cancer

Marth, C.Vulsteke, C.Rubio, M. J. R.Makker, V.Braicu, E. I.McNeish, I. A.Madry, R.Ayhan, A.Hasegawa, K.Wu, X.Dutta, L.Xu, C.Keefe, S.Lee, J.Pignata, S.2021-04-282021-04-2820200090-8258http://hdl.handle.net/11727/5769enginfo:eu-repo/semantics/closedAccessENGOT-en9/LEAP-001: A phase III, randomized, active-controlled, open-label study of pembrolizumab plus lenvatinib versus paclitaxel plus carboplatin for newly diagnosed advanced or recurrent endometrial cancerconferenceObject159221221000579556200474